Beyond Medical Technologies Inc Stock Price, News & Analysis

Beyond Medical Technologies (CSE: DOCT, OTC: DOCKF) has announced it will likely miss the April 30, 2025 deadline for filing its annual financial statements and related documents for the fiscal year ended December 31, 2024. The company has applied for a Management Cease Trade Order (MCTO) with the British Columbia Securities Commission due to delays caused by a recent management team transition.

The company expects to complete the Annual Filings by June 30, 2025. During the MCTO period, public trading of shares will continue, but company executives and certain insiders will be restricted from trading. Beyond Medical will issue bi-weekly status updates and comply with alternative information guidelines under National Policy 12-203.

Beyond Medical Technologies (CSE: DOCT, OTC: DOCKF) has announced significant corporate changes and strategic initiatives. The company implemented a complete executive leadership refresh in February 2025, appointing Daniel Liu as CEO, along with new directors and officers including Hongming Luo, Steven McAuley, Stevenson Ty as CFO, and Litong Cao as COO.

The company entered a licensing agreement with Ethsign for blockchain software, paying $25,000 through 192,308 shares at $0.13 per share. Beyond Medical is developing a blockchain attestation system for medical recordkeeping using Ethereum as its foundation.

Financially, the company has settled $395,000 of debt through share issuance and completed a $375,000 private placement, maintaining a current cash balance of CAD $172,018. The company aims to integrate blockchain-based attestations for medical record verification by Q2 2025. The previously announced Elite Horizon acquisition has been terminated.

Beyond Medical Technologies (CSE: DOCT, OTC: DOCKF) has announced a non-binding letter of intent to acquire Elite Horizon Management, a blockchain attestation platform specializing in secure documentation and financial verification. The proposed share exchange transaction would involve issuing up to 11,250,000 common shares to Horizon shareholders.

The acquisition aims to integrate blockchain technology for enhanced efficiency, security, and transparency in medical operations, focusing on smart contract verification and treasury management solutions. The deal is subject to due diligence, definitive agreement execution by March 31, 2025, and regulatory approvals.

Additionally, Beyond Medical has engaged Fairfax Partners for investor relations services, with a CAD $35,000 setup fee, CAD $7,500 monthly management fee, and CAD $50,000 marketing budget for a 12-month period.

Beyond Medical Technologies (CSE: DOCT, OTC: DOCKF) has announced three significant developments: First, the company has successfully repaid 68.7% of its outstanding debt by issuing 7.9 million common shares at $0.05 per share to settle $395,000 of debt obligations. Second, Steven McAuley has been appointed to the Board of Directors, bringing decades of experience in corporate governance and operational strategy. Third, Stevenson Ty has been named Interim Chief Financial Officer, replacing Jatin Baski. Ty brings extensive experience in corporate finance, treasury management, and regulatory compliance from previous executive finance roles.

Beyond Medical Technologies (CSE: DOCT, FSE: 7FM, OTC Pink: DOCKF) has announced a change in its board of directors. Hongming Luo has been appointed as a new director, bringing expertise in AI, Blockchain, Healthcare Tech, and derivatives markets. This appointment follows the resignation of Harveer Sidhu, effective February 4, 2025.

Beyond Medical Technologies (CSE: DOCT, OTC: DOCKF) has announced a significant leadership change with the appointment of Daniel Liu as Chief Executive Officer and director, effective January 30, 2025. Liu succeeds Kal Malhi, who has stepped down from his positions as CEO and director to pursue other ventures. While departing from his executive roles, Malhi will remain available as a consultant to the company as needed.

Beyond Medical Technologies Inc. (CSE: DOCT, FSE: 7FM, OTC Pink: DOCKF) has announced the resignation of Dr. Hyder A. Khoja from its Board of Directors. Dr. Khoja had served as an Independent Board Director since 2017. CEO Kal Malhi expressed gratitude for Dr. Khoja's service and wished him well in future endeavors.

The company has stated that it will begin a search for a new Independent Director and will inform the market once a suitable replacement has been interviewed and selected. This management change could potentially impact the company's governance structure and strategic direction.